Cysteine Modified Antibody-Drug Conjugate Homogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) lack site-specificity in conjugating cytotoxins to antibodies, leading to heterogeneity and increased side effects.
Innovation Solution
The development of cysteine modified antibody-cytotoxin conjugates, where cysteine is inserted into specific sites in the antibody, allowing for site-directed coupling with cytotoxins via a linker, maintaining antigen binding affinity and achieving homogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If non-site-specific conjugation is used to attach cytotoxins to antibodies, then the conjugation process is simpler, but the product heterogeneity increases and side effects worsen
Solution Approach 1:
The patent introduces site-specific cysteine residues at predetermined positions (e.g., LC 205, LC 206, or HC 474) in the antibody sequence, enabling conjugation to occur at specific local sites rather than throughout the entire antibody molecule. This localizes the conjugation reaction to defined regions, ensuring uniform DAR values and reducing product heterogeneity while maintaining manageable conjugation protocols
2Ease of manufacture
If non-site-specific conjugation is used to attach cytotoxins to antibodies, then the conjugation process is simpler, but side effects increase
Solution Approach 1:
By restricting conjugation to specific cysteine sites away from the antigen-binding region (CDR loops), the patent ensures that cytotoxin attachment does not interfere with antigen recognition and binding. This spatial separation minimizes off-target effects and maintains therapeutic safety while preserving the simplicity of the conjugation chemistry
Solution Approach 2:
The patent performs preliminary engineering of the antibody sequence to introduce site-specific cysteine residues at optimized positions before conjugation. This advance preparation ensures that subsequent conjugation occurs at predetermined safe sites, preventing harmful interactions with antigen-binding regions and reducing side effects before the actual drug attachment occurs
3Manufacturing precision
If site-specific cysteine insertion is used to conjugate cytotoxins, then conjugate homogeneity improves, but the antibody sequence complexity increases
Solution Approach 1:
The patent introduces cysteine residues at specific local positions (LC 205, LC 206, or HC 474) rather than throughout the entire antibody sequence. This localized modification approach achieves uniform conjugation (improving homogeneity) while minimizing the overall complexity increase, as only 1-3 specific positions are modified rather than the entire sequence
4Manufacturing precision
If site-specific cysteine insertion is used to conjugate cytotoxins, then conjugate homogeneity improves, but the number of conjugation sites increases
Solution Approach 1:
The patent strategically selects cysteine insertion positions that provide site-specific conjugation with controlled valency. By choosing positions like LC 205 or LC 206 in the light chain, the patent achieves homogeneous conjugation while limiting the number of active conjugation sites per antibody, thereby maintaining precision without excessive complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cysteine modified antibody-cytotoxin conjugates demonstrate improved homogeneity and reduced side effects compared to non-site-specific conjugated ADCs, with enhanced cytotoxic activity against cancer cells while preserving antigen binding affinity.
Implementation Method 1
the site-directed coupling of antibody-cytotoxin conjugate (TDC) by a cysteine thiol group with a linker-drug
Implementation Method 2
reducing the antibody with a reducing reagent (such as DTT, TCEP and the like) to provide a reduced antibody
Implementation Method 3
oxidizing the reduced antibody with an oxidant (such as DHAA, CuSO4) to re-connect interchain disulfide bonds of the antibody
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (-SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided. The specific insertion sites of cysteine are position 205 and/or position 206 (Kabat numbering scheme) of the light chain of the antibody, and/or position 439 (Kabat numbering scheme) of the heavy chain.